The drug maker signed a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercialization of the drug Baricitinib for COVID-19 indication in India.
In line with the licensing agreement, Natco Pharma has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for COVID-19 in India.
Natco Pharma had earlier received an emergency use authorization for Baricitinib tablets, from Central Drugs Standard Control Organization (COSCO), for use in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
For manufacturing and commercializing baricitinib in India Dr Reddys Laboratories announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for the manufacture and commercialization of the drug, baricitinib, in India.
The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the
treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company s existing range of COVID-19 therapeutics covering the full spectrum from mild to moderate
Abstract
An efficient methodology was developed to generate novel N,N0-dialkyl-2-thiobarbituric acid based sulfonamides S1–S4 in good to excellent yields 84%–95%. The synthesized compounds S1–S4 were docked to screen their in silico activities against two enzymes i.e., SARS-CoV-2 main protease enzyme with unliganded active site 2019-nCoV, coronavirus disease 2019, COVID-19 PDB ID: 6Y84 and SARS-CoV-2 M PDB ID: 6LU7. Furthermore, some in silico physicochemical and physicokinetic properties were evaluated using the OSIRIS Property Explorer, Molinspiration property calculator, ADMET property calculator, and GUSAR to assess these compounds as potential candidates as lead compounds for the quest of SARS-CoV-2 main protease inhibitors. Molecular docking analyses of the synthesized compounds predicted that compound S3 is more potent as SARS-CoV-2 main protease inhibitor with binding energy –11.65 kcal/mol in comparison with reference inhibitor N3 –10.95 kcal/mol, whereas compoun
The product is developed and manufactured by Indoco Remedies for TEVA at its facility in Goa.
The ANDA approved by the US Food and Drug Administration for Brinzolamide Ophthalmic
Suspension 1%, is used to treat high pressure inside the eye due to ocular hypertension and
open-angle glaucoma. Brinzolamide Ophthalmic Suspension 1% works by decreasing the
amount of fluid within the eye.
The US market size of this product is $184 million, according to IQVIA data as of December, 2020.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader,
Research and Markets: Europe Antibiotics Market Report 2021: Focus on Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, & Sulfonamides - Forecast to 2026 - ResearchAndMarkets.com
ResearchAndMarkets.com s offering.
The Europe Antibiotics Market is expected to witness market growth of 4.9% CAGR during the forecast period (2020-2026).
The rising case of bloodstream infections, pneumonia, and Urinary Tract Infections (UTI) is expected to boost the usage of carbapenems class of antibiotics.
The increasing threat of drug-resistance is the key factor for the development of advanced combinational formulations. For example, the advent of multi-resistance tuberculosis and infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) is hard to cure with antibiotics, thus, the development of advanced antibiotics is needed.